Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Inclusion Criteria: * Histologic diagnosis of NK/T Cell Lymphoma; * Age:18-80 years; * Eastern Cooperative Oncology Group (ECOG) status 0-3, Estimated survival time \> 3 months; * Normal haematological, liver and renal function (WBC count≥4×109/L, Hemoglobin≥100g/L, platelet count≥100×109/L, bilirubin\<1.5×ULN, Alanine transaminase (ALT) or Aspartate Aminotransferase (AST)\<2.5×ULN, serum creatinine\<1.5×ULN), normal coagulation function and cardiac function; * Appreciable and measurable lesions ; * No history of other malignancies; * No previous treatments including chemotherapy, radiotherapy, targeted therapy or stem cell transplantation; * No other serious diseases which conflict with the treatment in the present trial; * No concurrent treatments that conflict with the treatments in the present trial(including steroid drugs); * Voluntary participation and signed the informed consent. Exclusion Criteria: * The patients had the conditions below: clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), symptomatic coronary artery heart disease requiring medication; * The patients suffered from organ transplant * The patients participated in other clinical trials within the 30 days before enrollment or who are participating in other clinical studies; * The patients with active bleeding or new thrombotic disease, who are taking anticoagulant drugs or with a history of bleeding tendencies; * The patients suffered before surgery less than four weeks, or after less than six weeks; * The patients with major vascular invasion; * The patients with abnormal liver function (total bilirubin\> 1.5 times the normal value, ALT / AST\> 2.5 times normal), abnormal renal function (serum creatinine\> 1.5 times normal), blood abnormalities (absolute neutrophil count \<1.5 × 109 / L, platelets \<80 × 109 / L, hemoglobin \<90g /L) ; * The patients with moderate to severe proteinuria; * Severe hypertension,BP≥160/100mmHg; * The patients with mentally ill / unable to obtain informed consent; * The patients with drug addiction, alcohol abuse which affects the long-term evaluation of test results; * The patients in pregnancy, lactation and women of childbearing age who do not want to take contraceptive measures subjects; * Clinical and laboratory support brain metastases; * The patients with a history of allergy to test drug; * The patients not suitable to participate in the investigator judged by researchers.